This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Abstract Details
Activity Number:
|
360
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 3, 2010 : 10:30 AM to 12:20 PM
|
Sponsor:
|
Biometrics Section
|
Abstract - #309056 |
Title:
|
Using Statistical Concepts to Determine Risk Level of Randomized Clinical Trials That Compare Two Noninvestigational Therapies
|
Author(s):
|
Martin L. Lesser and Nina E. Kohn*+
|
Companies:
|
Feinstein Institute for Medical Research
|
Address:
|
Biostatistics Unit, Manhasset, NY, 11030,
|
Keywords:
|
research risk assessment ;
randomized trials ;
IRB
|
Abstract:
|
Statistical thinking can help decide if a randomized clinical trial (RCT) can be considered no more than minimal risk (MR) even if the therapies (tx) do include risks. A study is MR if the risks are not greater than those ordinarily encountered in daily life or routine medical procedures. We argue: A RCT comparing 2 commonly used non-investigational tx's, may not increase risk above MR. Let T1, T2 be 2 tx's with risk benefit ratios (RBR) RB1, RB2. Assume a patient (pt) receives T1 or T2 with probabilities p,1-p outside of the RCT (p="community" prob of T1 usage). The expected "community" RBR is r=p*RB1+(1-p)*RB2. In a RCT where v=prob(pt is randomized to T1), the expected RCT RBR is R=v*RB1+(1-v)*RB2. Assuming tx's encountered by a pt are considered "routine" for that pt and are, therefore, considered MR, then, by subjectively comparing r and R, an IRB can decide if the RCT is MR.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2010 program
|
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.